文献速递肝病

24-去甲熊去氧胆酸重塑CD8+ T细胞免疫代谢并减轻肝脏炎症

24-Norursodeoxycholic acid reshapes immunometabolism in CD8+ T cells and alleviates hepatic inflammation.
PubMed 文献 · J Hepatol · 2021-07-07

该研究探究24-去甲熊去氧胆酸(NorUDCA)对CD8+ T细胞的直接免疫调节作用。在Mdr2-/-胆汁淤积模型和急性LCMV感染非胆汁淤积模型中,NorUDCA减少肝脏CD8+ T细胞、改善肝损伤和全身炎症,机制涉及抑制CD8+ T细胞淋巴母细胞生成、扩增、糖酵解及mTORC1信号,并在PSC患者循环CD8+ T细胞中验证。

要点

  • NorUDCA直接调节CD8+ T细胞功能,减轻其驱动的肝脏免疫病理。
  • 机制上NorUDCA靶向mTORC1信号,抑制CD8+ T细胞糖酵解和扩增。
  • 在PSC患者循环CD8+ T细胞中验证了NorUDCA对mTORC1信号的影响。

核心结论

  • NorUDCA对CD8+ T细胞具有直接调节作用,可减轻过度的CD8+ T细胞驱动的肝脏免疫病理。
  • 这些发现对原发性硬化性胆管炎(PSC)等免疫介导肝病的治疗具有相关性。

研究设计与样本

  • 研究在Mdr2-/-小鼠(PSC胆汁淤积模型)中观察NorUDCA的免疫调节作用。
  • 采用急性非溶细胞性淋巴细胞脉络丛脑膜炎病毒(LCMV)感染诱导的CD8+ T细胞驱动非胆汁淤积性肝损伤模型。
  • 方法包括分子与生化方法、流式细胞术、小鼠CD8+ T细胞体外代谢实验及质谱分析。
  • 在PSC患者循环T细胞中验证小鼠细胞中观察到的信号效应。

主要发现

  • 在Mdr2-/-模型中,NorUDCA减少肝脏固有和适应性免疫细胞,包括CD8+ T细胞。
  • 在急性LCMV感染的非胆汁淤积模型中,NorUDCA改善肝损伤和全身炎症。
  • NorUDCA对CD8+ T细胞发挥强免疫调节作用,影响淋巴母细胞生成、扩增、糖酵解和mTORC1信号。
  • 质谱鉴定NorUDCA通过靶向mTORC1调节CD8+ T细胞。
  • NorUDCA对mTORC1信号的影响在PSC患者循环CD8+ T细胞中得到进一步确认。

临床怎么用

  • NorUDCA可能通过直接抑制CD8+ T细胞mTORC1信号和糖酵解,减轻免疫介导肝病(如PSC)的肝损伤。
  • 该机制为NorUDCA治疗PSC等免疫介导肝病提供了免疫代谢调节层面的理论依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: 24-Norursodeoxycholic acid (NorUDCA) is a novel therapeutic bile acid used to treat immune-mediated cholestatic liver diseases, such as primary sclerosing cholangitis (PSC), where dysregulated T cells including CD8+ T cells contribute to hepatobiliary immunopathology. We hypothesized that NorUDCA may directly modulate CD8+ T cell function thus contributing to its therapeutic efficacy. METHODS: NorUDCA's immunomodulatory effects were first studied in Mdr2-/- mice, as a cholestatic model of PSC. To differentiate NorUDCA's immunomodulatory effects on CD8+ T cell function from its anticholestatic actions, we also used a non-cholestatic model of hepatic injury induced by an excessive CD8+ T cell immune response upon acute non-cytolytic lymphocytic choriomeningitis virus (LCMV) infection. Studies included molecular and biochemical approaches, flow cytometry and metabolic assays in murine CD8+ T cells in vitro. Mass spectrometry was used to identify potential CD8+ T cell targets modulated by NorUDCA. The signaling effects of NorUDCA observed in murine cells were validated in circulating T cells from patients with PSC. RESULTS: NorUDCA demonstrated immunomodulatory effects by reducing hepatic innate and adaptive immune cells, including CD8+ T cells in the Mdr2-/- model. In the non-cholestatic model of CD8+ T cell-driven immunopathology induced by acute LCMV infection, NorUDCA ameliorated hepatic injury and systemic inflammation. Mechanistically, NorUDCA demonstrated strong immunomodulatory efficacy in CD8+ T cells affecting lymphoblastogenesis, expansion, glycolysis and mTORC1 signaling. Mass spectrometry identified that NorUDCA regulates CD8+ T cells by targeting mTORC1. NorUDCA's impact on mTORC1 signaling was further confirmed in circulating PSC CD8+ T cells. CONCLUSIONS: NorUDCA has a direct modulatory impact on CD8+ T cells and attenuates excessive CD8+ T cell-driven hepatic immunopathology. These findings are relevant for treatment of immune-mediated liver diseases such as PSC. LAY SUMMARY: Elucidating the mechanisms by which 24-norursodeoxycholic acid (NorUDCA) works for the treatment of immune-mediated liver diseases, such as primary sclerosing cholangitis, is of considerable clinical interest. Herein, we uncovered an unrecognized property of NorUDCA in the immunometabolic regulation of CD8+ T cells, which has therapeutic relevance for immune-mediated liver diseases, including PSC.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Zhu C, Boucheron N, Müller AC, et al. 24-Norursodeoxycholic acid reshapes immunometabolism in CD8+ T cells and alleviates hepatic inflammation. J Hepatol. 2021. PMID: 34242699. doi:10.1016/j.jhep.2021.06.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。